Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A syndrome characterized by intellectual deficit, spasticity in the lower limbs (spastic paraplegia), pes cavus deformity of both feet, an abnormal gait, and palmar and plantar hyperkeratosis. It has been reported in four brothers. The mother of the affected boys had normal intelligence, plantar hyperkeratosis and a strong facial resemblance to her retarded sons. Her three daughters were normal. This syndrome most likely an X-linked recessive condition.
Features include very common findings: Spastic paraplegia, Intellectual disability, Palmoplantar keratoderma, and Abnormal fingernail morphology and others; and common findings: Brisk reflexes, Sloping forehead, Micrognathia, and High forehead and others. 26 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 7 | Mild intellectual disability, Spastic paraplegia, Intellectual disability |
Biomarker and diagnostic research for paraplegia-intellectual disability-hyperkeratosis syndrome has been reported in the published literature.
Phenotype severity distribution: 9 very common features, 9 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for paraplegia-intellectual disability-hyperkeratosis syndrome.
201 publications have been identified in PubMed for paraplegia-intellectual disability-hyperkeratosis syndrome. Kisho has analyzed 138 by research type. Research spans Review / Meta-Analysis (62%), Basic Science / Preclinical (13%), and Epidemiology / Natural History (8%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 85 | 62% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 5:32 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Skin | 2 | Palmoplantar hyperkeratosis, Palmoplantar keratoderma |
Eyes | 2 | Ptosis, Nystagmus |
Arms and legs | 2 | Abnormal fingernail morphology, Lower limb spasticity |
Head and neck | 1 | High palate |
Bones and joints | 1 | Joint hypermobility |
Laboratory research |
18 |
13% |
Disease patterns and progression | 11 | 8% |
Patient case studies | 10 | 7% |
Other research | 7 | 5% |
Testing and diagnosis research | 3 | 2% |
Clinical study results | 3 | 2% |
New treatment approaches | 1 | 1% |
Gąsiorowska J (2026). [PMID: 42023627](https://pubmed.ncbi.nlm.nih.gov/42023627/). *Pediatr Endocrinol Diabetes Metab*. [Review / Meta-Analysis]
Anderson EN (2026). [PMID: 41468891](https://pubmed.ncbi.nlm.nih.gov/41468891/). *Am J Hum Genet*. [Basic Science / Preclinical]
Amado C (2026). [PMID: 40975490](https://pubmed.ncbi.nlm.nih.gov/40975490/). *Ann Allergy Asthma Immunol*. [Review / Meta-Analysis]
Ferri C (2026). [PMID: 41798958](https://pubmed.ncbi.nlm.nih.gov/41798958/). *Front Immunol*. [Review / Meta-Analysis]
Papazachariou A (2026). [PMID: 41128447](https://pubmed.ncbi.nlm.nih.gov/41128447/). *Curr Opin Clin Nutr Metab Care*. [Review / Meta-Analysis]
Lee S (2026). [PMID: 41206258](https://pubmed.ncbi.nlm.nih.gov/41206258/). *Am J Geriatr Psychiatry*. [Review / Meta-Analysis]
Pignataro G (2025). [PMID: 41010942](https://pubmed.ncbi.nlm.nih.gov/41010942/). *Medicina (Kaunas)*. [Review / Meta-Analysis]
Karuntu JS (2025). [PMID: 39733931](https://pubmed.ncbi.nlm.nih.gov/39733931/). *Prog Retin Eye Res*. [Review / Meta-Analysis]
Sahoo SS (2025). [PMID: 39475954](https://pubmed.ncbi.nlm.nih.gov/39475954/). *Blood*. [Review / Meta-Analysis]
Kaul A (2025). [PMID: 40915300](https://pubmed.ncbi.nlm.nih.gov/40915300/). *Lancet Rheumatol*. [Review / Meta-Analysis]